Previous 10 | Next 10 |
Gainers: ChemoCentryx CCXI +57%, ReShape Lifesciences (NASDAQ:RSLS) +30%, Voyager Therapeutics VYGR +13%, Sundial Growers (NASDAQ:SNDL) +10%, Flora Growth (NASDAQ:FLGC) +6%. Losers: Allogene Therapeutics ALLO -42%, Cellectis CLLS -19%,...
Calyxt has refined its business strategy further to a pure trait/technology licensing model, but hasn't announced any major new licensing partnerships since its deal with S&W for alfalfa. The company has a credible pipeline of value-added products that should generate some interes...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips In the 1980s, the field of genetics surged in popularity. At the time, I’m sure there were many articles promising investors that genetics stocks were on the cusp of spectacular gains. Investors who were looking for ...
MaxCyte has become the go-to partner for biotech companies using non-viral cell engineering, aided by its proprietary patented flow electroporation technology. The company has a scalable (licenses and SPLs) business model with recurring revenues. Milestone and royalty payments (at 100...
NEW YORK, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy pro...
Image source: The Motley Fool. Cellectis SA (NASDAQ: CLLS) Q2 2021 Earnings Call Aug 6, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Cellectis SA (CLLS) Q2 2021 Earnings Call Transcript
Cellectis S.A. (CLLS) Q2 2021 Earnings Conference Call August 6, 2021 08:00 AM ET Company Participants Eric Dutang - Chief Financial Officer André Choulika - Chief Executive Officer Carrie Brownstein - Chief Medical Officer Steve Doares - Senior Vice President, US Manufacturing Conferenc...
• Preliminary translational data validate UCARTCS1 as a promising potential therapy for relapsed or refractory multiple myeloma patients. • Preclinical pipeline disclosed at Innovation Days : UCART20x22 for B-cell malignancies, UCARTMESO (targeting mesotheli...
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR) T-cells and g...
Phase I trials mean more usual for Cellectis. Cellectis is pursuing low-hanging fruit indications. New pipeline programs and their IP position offer upside on top of their CAR-T programs. For further details see: Cellectis Offers An Idiosyncratic Risk Profile With Remark...
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...